A Double Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Interferon Alfa-N3 Therapy in Addition to Standard of Care in Adults Hospitalized Due to Acute Severe Influenza.

Trial Profile

A Double Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Interferon Alfa-N3 Therapy in Addition to Standard of Care in Adults Hospitalized Due to Acute Severe Influenza.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Interferon alpha-n3 (Primary)
  • Indications Influenza A virus H1N1 subtype; Influenza virus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jan 2011 In a company media release, Hemipherex announced that the UD FDA has lifted a clinical hold on this trial, following a review of a submission which provided complete response to the Agency's reasons for the clinical hold.
    • 04 Aug 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top